CompletedInterventionalEarly Phase 1Last updated Mar 25, 2021

Rosuvastatin (Crestor) in Friedreich Ataxia

Open-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich Ataxia

Overview

ClinicalTrials.gov ID: NCT02705547
Lead Sponsor: Children's Hospital of PhiladelphiaOTHER
Brief Summary: This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvastatin daily for three months.
Study Type

Status

Study Record Dates

NCT01921868Unknown status

An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia

NCT01339884Completed

A Study of Resveratrol as Treatment for Friedreich Ataxia

NCT03933163Completed

Micronised Resveratrol as a Treatment for Friedreich Ataxia

NCT04649866Completed

Coronary Artery Disease in Patients With Friedreich's Ataxia

NCT04102501Completed

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

NCT01078675Completed

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia